Safety and effectiveness of antimalarial therapy in sickle cell disease: a systematic review and network meta-analysis

Table 2 Assessment of risk of bias of studies included in the meta-analysis

Author details	Study site	Drug regimen	Allocation sequence	Allocation concealment	Blinding	No evidence of incomplete outcome data recording	No evidence of selective outcome recording
Olaosebikan et al., 2015	Kwara state, Nigeria	MQAS SPAQ PG	Yes	Yes	(Open-label) Laboratory staff were unaware of treatment allocation	MQAS (2 withdrew consent, 3 moved away, 12 lost and 4 deaths) SPAQ (1 withdrew consent, 2 moved away and 12 lost) PG (1 moved away, 26 lost and 3 deaths)	Yes ^b
Diop et al., 2010	Dakar, Senegal	PL SP	Yes	Yes	Open-label	Yes^a	Yes ^b
Nakibuuka et al., 2009	Kampala, Uganda	SP CQ	Yes	Yes	Double-blind	SP (7 lost to follow up) CQ (8 lost to follow up)	Yes ^b
Eke et al., 2003	Port Harcourt, Nigeria	PL PM PG	Yes	Yes	Open-label	Yes^a	Yes ^b
Nwokolo et al., 2001	Multicenter, Nigeria	PG MQ	Yes	Yes	Open-label	Yes^a	Yes ^b
Warley et al., 1965	Kampala, Uganda	PL CQ + benzathine penicillin	Yes	Yes	Not provided	Yes^a	No (dactylitis and Haemoglobin)

CQ = Chloroquine, MQ = Mefloquine, MQAS = Mefloquine-artesunate, PL = Placebo, PG = Proguanil, SP=Sulfadoxine-pyrimethamine, SPAQ = Sulfadoxine pyrimethamine-amodiaquine
^aYes indicates that there is no evidence of incomplete outcome data recording
^b Yes indicates that there is no evidence of selective outcome recording

ISSN: 1471-2334